Structure creative deals with large biopharma, and medical devices companies seeking to externalize R&D via partnerships.


UNDERSTANDING THE PROCESS

“When Should I Partner?”
“Am I Ready to Partner?”
Define Goals Including Timelines
Alternative Corporate Structures (LLC, C-Corp)
Alternative Licensing Structures (Early Pharma Structured Buyouts)

CORE DOCUMENT PREPARATION

Executive Summary
Management Presentation
Financial Valuation/Modeling


Identify, Communicate, Manage Licensing Agreements w/Strategics

Identify – SJA “Rolodex” and Data Analytics (HealthiosXchange, Capbridge)

Communicate – Online (inbound marketing, social media), Offline (partnering events, one-on-one’s)

Manage/Due Diligence

Negotiation

Term Sheets

Full Agreement

CLOSE – WIN



CREATIVE DEAL STRUCTURING – “External R&D”

Direct External Innovation Models – Partnering Around a
Specific Company/Project

  • Venture Co-Creation — Large Pharma/Medical Device participals with venture capital firms in early moments of launching a company
  • Built-to-Buy-Deals — Asset-centric drug discovery startups with pre-defined acquisition rights at Development Company nomination
  • Broad Company Accelerating R&D Collaborations
    • Upfront capital in exchange for pre-specified product rights (e.g. Agios/Celgene)

Fund Related Portfolio Approaches – Large Pharma/Medical Device Expand Reach and Exposure to Innovation

  • Corporate Venture Capital — Syndicate partners of choice in the early-stage arena
  • Limited Partnership Commitments — To established venture funds
  • Option Funds — Either in-house funds with product rights or LP-relationships where Pharma/Medical Device gains direct rights to option-in or access the underlying investments in the portfolio